Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
JCO Precision Oncology|February 9, 2022
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.The New England Journal of Medicine|April 30, 2015
Rociletinib in EGFR-mutated non-small-cell lung cancerLecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.Cancer|November 11, 2017
Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challengesMarshall L Spiegel, Jonathan W Goldman, Brian R Wolf, et al.Journal of the National Comprehensive Cancer Network : JNCCN|December 13, 2021
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyApar Kishor P Ganti, Billy W Loo, Michael Bassetti, et al.Cancer Discovery|November 17, 2019
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerLawrence Fong, Andrew Hotson, John D Powderly, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026Apar Kishor P Ganti, Billy W Loo, Shahed Badiyan, et al.The New England Journal of Medicine|March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic CancerWungki Park, Anup Kasi, Alexander I Spira, et al.Nature Medicine|March 28, 2024
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim resultsAmy R Rappaport, Chrisann Kyi, Monica Lane, et al.The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.Pageof 12